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Leishmania parasites are able to secure their survival and propagation within their host by altering signalling pathways involved in
the ability of macrophages to kill pathogens or to engage adaptive immune system. An important step in this immune evasion pro-
cess is the activation of host protein tyrosine phosphatase SHP-1 by Leishmania. SHP-1 has been shown to directly inactivate JAK2
and Erk1/2 and to play a role in the negative regulation of several transcription factors involved in macrophage activation. These
signalling alterations contribute to the inactivation of critical macrophage functions (e.g., Nitric oxide, IL-12, and TNF-α). Addi-
tionally, to interfere with IFN-γ receptor signalling, Leishmania also alters several LPS-mediated responses. Recent ﬁndings from
our laboratory revealed a pivotal role for SHP-1 in the inhibition of TLR-induced macrophage activation through binding to and
inactivatingIL-1-receptor-associatedkinase1(IRAK-1).Furthermore,weidentiﬁedthebindingsiteasanevolutionarilyconserved
ITIM-like motif, which we named kinase tyrosine-based inhibitory motif (KTIM). Collectively, a better understanding of the eva-
sion mechanisms utilized by Leishmania parasite could help to develop more eﬃcient antileishmanial therapies in the near future.
1.Background
Apart from the impact of Leishmania on world health, Leish-
maniasisrepresentsanelegantinfectionmodelthatcanteach
us a lot about host-parasite interactions and immune eva-
sion. This parasite has the ability to enter host macrophages
(M∅s) safely and replicate inside the very same phagocytes
that were recruited to destroy it. The inability of M∅s to kill
the parasite and activate cells of the adaptive immune system
is a product of the parasite’s long-reported capacity to alter
several key signalling pathways in the host. Many signalling
alterations are seenearly in the courseof infection suggesting
they start upon the initial contact between the parasite and
the M∅. These rapid alterations of signalling pathways serve
at least two main functions: ﬁrstly, inhibition of M∅ killing
mechanisms that are triggered upon phagocytosis of foreign
particles (e.g., production of reactive oxygen species), and
secondly, inhibition of leishmanicidal functions that can be
triggered in response to M∅ activation in infected tissues
in response to stimuli such as lipopolysaccharides (LPS) or
interferon-γ (IFN-γ) (e.g., nitric oxide production). In this
review, we will discuss the roles of Leishmania in disease
establishment, focusing on the signalling pathways that they
interfere with and the M∅ functions that are aﬀected by the
alteration of these pathways.
2. Alteration of Macrophage Signalling
Moleculesby Leishmania
Severalpathogens(i.e.,Acanthocheilonemaviteae[1],African
trypanosomes [2], and Toxoplasma gondii [3] )a r ea b l et o
alter the signalling of their target cells to their own advantage
and Leishmania is no exception. Leishmania achieves this
by either employing strategies to inhibit proteins that play
a positive role in immune cell activation or by activating
molecules known to play key roles in the negative regulation
of immune cell signalling and function [4]. We will discuss
below the main signalling molecules altered by Leishmania
in an eﬀort of the parasite to survive inside host M∅s.2 Journal of Tropical Medicine
Firstly, protein kinase C (PKC), a protein family com-
prising 10 serine/threonine kinases, initially characterized as
Ca+2 and phospholipid dependent [5, 6], is classiﬁed into
three subfamilies: the conventional (PKC-α,- βI, -βII, and
-γ), novel (PKC-δ,- ε,- η,a n d- τ), and atypical (PKC-ζ and
-λ)i s o f o r m s[ 7]. PKC signalling is known to play a key role
in the regulation of M∅ functions activating, for instance,
cytokines such as IFN-γ and TNF-α [8, 9], both having
important roles in driving several M∅ functions including
NO production [8] and oxidative burst [10]. Promastigote
LPG has been described to be able to block PKC activity [11–
13]. This inhibition is achieved through the binding of LPG
to the regulatory domain of PKC which contains the DAG,
Ca+2, and phospholipid binding sites [14]. It is interesting
to observe that amastigotes, which lack LPG, are also able
to inhibit PKC activity in monocytes [15], suggesting that
factorsotherthanLPGcanalsomediatethisinhibitoryeﬀect.
Indeed, Leishmania-induced ceramide generation [16]a n d
GIPLs [12] have been shown to be able to do so, providing
a possible mechanism whereby amastigotes can inhibit PKC
activity.
Later on, Janus kinase 2 (JAK2) as one of four members
of the Janus family of tyrosine kinases (JAK1, JAK2, JAK3,
and TYK2), has been identiﬁed to be importantly aﬀected by
Leishmania infection. JAK activation plays an important role
in cell proliferation, diﬀerentiation, migration, apoptosis,
and immune activation [17]. The JAK signalling pathway is
initiated when a cytokine or a growth factor binds to its re-
ceptor inducing receptor multimerization followed by JAKs
transphosphorylation and activation, ultimately leading to
the phosphorylation of signal transducer and activator of
transcription (STAT), a transcription factor (TF), that will
thendimerizeandproceedtonucleusbytranslocationandto
bind target regulatory sequences to activate or repress tran-
scription [17, 18].
Importantly,theiNOSgenepromoterresponsibleforNO
production has binding sites for several TFs including STAT-
1[ 19, 20]. Leishmania has the ability to block the JAK/STAT
signalling pathway in response to IFN-γ stimulation, there-
fore avoiding the induction of NO. Indeed, it has been
reportedthatinfectionwithL.donovaniamastigoteswasable
to block IFN-γ-induced JAK1, JAK2, and STAT-1 phospho-
rylation in PMA-diﬀerentiated U-937 promonocytic cells
and human monocytes [21]. However, we went further in
studying the eﬀect of Leishmania on JAK2 phosphorylation
by reporting that L. donovani promastigotes were rapidly
activating host SHP-1 leading to the subsequent inhibition
of IFN-λ-induced JAK2 phosphorylation [22], see Figure 1.
Others have suggested that IFN-γ unresponsiveness to stim-
ulation can be due to the inhibition of the IFN-γ receptor
(IFN-γR) complex formation [23], however they did not
provide any clues on how the parasite could do so. Another
complication with this report is that the authors infected
cells for 24 hours to see an appreciable eﬀect on receptor
expression and phosphorylation, which cannot explain the
rapid dephosphorylation of JAK2 seen when BMDMs are
infected with Leishmania promastigotes [22], supporting
the notion that early JAK/STAT inhibition must depend on
parasite-induced alterations of existing signalling molecules
of the host and not on alterations at the transcriptional
level.
In the same line of ideas, several members of the mito-
gen-activated protein kinases (MAPKs) family (e.g., extra-
cellular signal-regulated kinase1/2 (Erk1/2), proline for Jun
N-terminal kinase (JNK), and glycine for p38), known to
play critical role in the activation of several TFs [24], have
beenfoundtobeexploitedbyLeishmaniaparasite(Figure 1).
Indeed, as was the case with the JAK family, it is remarkable,
though not unexpected, that the Leishmania parasite devel-
oped tactics to render several MAPK members inactive in
response to parasite entry to M∅s or to activating stimuli
that follow infection. For instance, it was reported that the
phagocytosis of L. donovani promastigotes by naive M∅s
does not lead to the activation of any of the three MAPKs
(Erk1/2, JNK, p38) [25]. Furthermore, activation of several
MAPKs in response to LPS has been shown to be inhibited
in infected cells. For instance, L. amazonensis amastigotes are
abletoblockLPS-mediatedErk1phosphorylationininfected
M∅s[ 26], and L. donovani amastigotes can block PMA-
induced Erk1/2 phosphorylation in RAW264 M∅s leading
to the inhibition of Elk-1 and c-fos expression [27]. The
authors of the latter study suggested a role for host PTPs in
Erk1/2inactivation, ahypothesis supportedandmore deeply
explored by our laboratory where we provided evidence that
PTP-SHP-1 is able to dephosphorylate and inactivate Erk1/2
through demonstrating that this MAPK was still able to
be activated in Leishmania-infected SHP-1-deﬁcient M∅s
in response to IFN-γ stimulation [28]. Alternatively, it has
been suggested that ceramide production by L. donovani-
infected M∅s can lead to reduce Erk1/2 phosphorylation
[29]. Interestingly, amastigotes of L. mexicana were also
reported to inhibit Erk1/2 signalling not by inhibiting their
phosphorylation, but rather by degrading them using the
parasite’s cysteine proteinases. Similar cysteine proteinase-
dependent degradation was observed for JNK [30].
In regard to p38, it has been shown that this MAPK is
nonresponsive when M∅s infected with L. major are stim-
ulated with a CD40 antibody to mimic the M∅-T cell in-
teraction. p38 inactivation correlated with impaired iNOS2
expression and NO production and therefore impaired leish-
manicidal functions [31]. In fact, this inactivation makes
sense in the light of experiments showing the importance
of p38 activation in the control of Leishmania infection. The
use of anisomycin, a p38 activator, enhanced parasite killing
in M∅s by triggering p38-dependent antileishmanial eﬀects
[31, 32].
In order to inhibit gene expression of proinﬂammatory
cytokinesandmicrobicidalmolecules,Leishmaniadeveloped
several strategies to interfere with TFs that bind to the pro-
motersofthosegenes.SeveralTFsareinvolvedinthisprocess
including NF-κB, STAT-1α, and AP-1, all of which known
to be modulated by the parasite. In fact, several groups
have reported diﬀerent strategies employed by Leishmania
to alter, for instance, the TF NF-κB. Leishmania-induced
ceramide generation by M∅s was shown to play a role in
NF-κB inhibition [29]. One study provided evidence that
L. major amastigotes blocked the nuclear translocation of
the p65/p50 complex selectively favouring the c-Rel/p50Journal of Tropical Medicine 3
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Figure 1: Downregulation of macrophages signalling by Leishmania infection. Leishmania infection modulates phosphatases (SHP-1 and PTP-
1B) activity by mechanism involving the metalloprotease gp63. SHP-1 was found to interact with IRAK-1, a key kinase involved on TLR-
triggered signaling pathway. Whereas, both SHP-1 and PTP-1B are involved in the downregulation of IFNγ-induced pathway (JAK/STAT1)
as well as MAPK activation. In addition, transcription factor such as NF-κB and AP-1 are cleaved/degraded in part by Leishmania gp63.
Orange arrows indicate gp63 involved modulation; black arrows indicate activation; red abrogated lines indicate downregulation.
complex that, they proposed, plays a role in the gene ex-
pression of immunosuppressive cytokines in M∅ss u c ha s
IL-10 [33]. Another study reported that cysteine proteinases
of L. mexicana mediated NF-κB degradation and caused its
inability to bind its DNA consensus sequence, thus partially
explaining how the parasite can inhibit LPS-mediated IL-
12 production [30]. Work from our laboratory showed that
promastigotes of several pathogenic Leishmania species were
able to cleave the p65 RelA subunit to generate a p35 RelA
fragment translocating to the nucleus and bind DNA. This
p35 fragment was suggested to be involved in the parasite’s
ability to drive NF-κB-mediated chemokine gene expression
in infected M∅s[ 34].
In addition to NF-κB and the fact we have previously
described Leishmania’s ability to inhibit the JAK/STAT path-
way [22], our laboratory has also reported that the parasite is
able to repress IFN-γ-mediated signalling in M∅s by inter-
feringwithSTATs.WeshowedthatL.donovanipromastigotes
wereabletocauseproteasome-mediatedSTAT-1degradation
in infected M∅s. However, whereas STAT-1 degradation was
reversed using proteasome inhibitors [35], its capacity to
respond to IFN-γ was still altered due to JAK2 inactivation
(unpublished data).
AP-1 is a structurally complex TF formed by dimmers
from Jun and Fos protein family [36] that can be activated by
many kinds of stimuli such as growth factors, cytokines, hor-
mones, and pathogens, which do so using several signalling
molecules. Consequently, the previously mentioned tactics
employed by Leishmania to interfere with PKC, Erk1/2, JNK,
and p38 activities have a direct impact on the ability of
the parasite to block AP-1 signalling in M∅s. Importantly,
work from our group demonstrated a role for SHP-1 in AP-
1 inhibition [28, 37] and, more recently, that the parasite’s
surface protease gp63 is responsible for the cleavage and
degradation of key AP-1 subunits [38]. The latter ﬁnding
provides the ﬁrst demonstration that a parasite-derived
molecule can directly interfere with AP-1 in host M∅si n
order to block its downstream functions.
3. Negative Regulation by Protein
TyrosinePhosphatases
Protein tyrosine phosphatases (PTPs) are proteins that have
the ability to dephosphorylate substrates and are divided
into receptor-like and nonreceptor PTPs. Nonreceptor PTPs
can either dephosphorylate tyrosines only or can possess
dual speciﬁcity dephosphorylating tyrosines as well as ser-
ines/threonines [39]. One common feature of PTPs is the
presence of a PTPs catalytic domain in which a critical
cysteine is found within a conserved signature motif,4 Journal of Tropical Medicine
(I/V)HCxxGxxR(S/T), and mediates the hydrolysis via the
formation of a thiophosphate intermediate [40]. Receptor-
like PTPs include RPTP-α, CD45, and CD148, and the
function of some like CD45 in immune cell signalling are
well known [41]. However, herein we will focus on a selected
group of soluble PTPs that have been shown to play a role
in Leishmania host evasion mechanisms, namely, PTP-1B,
TC-PTP, PTP-PEST, and most importantly SHP-1. PTP-1B
and TC (T cell)-PTP: they are two ubiquitously expressed
PTPs that have more than 73% identity in their catalytic
domain [42]. PTP-1B is known to play important regulatory
functions in metabolism, as demonstrated by the insulin
hypersensitivity of PTP-1B−/− mice and their resistance to
high-fat-diet-induced obesity [43, 44]. This insulin hyper-
sensitivity was shown to be due to the ability of PTP-1B
to dephosphorylate the insulin receptor [45]. PTP-1B also
seems to play a role in the regulation of cytokine signalling
through its ability to interact with and dephosphorylate
members of the JAK family, namely, JAK2 and TYK2 [46].
In addition to PTP-1B’s role in the regulation of JAK/STAT
signalling, a role for this phosphatase in the regulation of
TLR4 signalling was proposed. PTP-1B−/− M∅s had in-
creased LPS-induced iNOS expression and NO production
compared to WT M∅s and were more susceptible to
endotoxic shock following low-dose LPS injection [41]. As
PTP-1B was found to be an important negative regulator of
M∅s signaling, its role in Leishmaniasis could be critical. In
fact, we recently showed that Leishmania gp63 was able to
enhance PTP-1B activation by cleaving it. PTP-1B activity
seems to inhibit M∅ a c t i v a t i o na n dh e l pi np a r a s i t es u r v i v a l
as seen in the delayed onset of footpad swelling and reduced
parasite burden in PTP-1B−/− mice infected with L. major
[47]. In addition, we found that TC-PTP that also plays
important roles in the negative regulation of JAK1, JAK3
[48], and nuclear STAT-1 [49] was modulated by gp63 in
Leishmania-infected M∅s[ 47]. This gp63-mediated TC-
PTP cleavage along with the cleavage of PTP-PEST was
recently reported by our group and M.L. Tremblay’s group to
enhance the catalytic activity of the PTPs in question and/or
allowthemtoaccessadditionalsubstratesthatmighthelpthe
parasite establish itself [50].
Another PTP modulated by Leishmania gp63 is SHP-1.
This PTP contains two N-terminal SH2 domains (N-SH2,
C-SH2), followed by a PTP domain responsible for dephos-
phorylating substrates, and a C-terminal tail [41]. This phos-
phatase is mostly expressed in hematopoietic cells [51, 52],
but is also expressed at lower levels in epithelial [52], endo-
thelial [53, 54], and central nervous system cells [55]. The
SH2 domains have two main functions: ﬁrstly, the N-SH2
domainplaysanimportantautoinhibitoryrolebyinteracting
intramolecularly with the PTP domain, keeping the PTP in
the inactive state. Secondly, both SH2 domains have the abil-
ity to bind to phosphotyrosine (p-Y) residues usually found
within immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) whose consensus sequence is (I/V/L/S)xYxx(L/V)
[36]. This second feature of SH2-domains is thought to play
a role in the detachment of the N-SH2 from the PTP domain
once the C-SH2 domain binds to a target p-Y, therefore
opening up and activating the PTP [41].
At the signalling level, our laboratory have clearly dem-
onstrated that Leishmania was able to rapidly activate host
SHP-1 causing SHP-1-mediated JAK2 inactivation in M∅s
[22]. Additionally, we and others have implicated SHP-1
in the negative regulation of Erk1/2 activity [27, 28]a n d
in the regulation of the downstream TFs NF-κB and AP-1
[28]duringLeishmaniainfection.Atthefunctionallevel,our
laboratory showed that the injection of PTP inhibitors (bpV-
phen, a bis-peroxovanadium compounds) to mice infected
with L. major or L. donovani helped control the infection
[56] in a manner dependent on iNOS expression and NO
production [57]. Furthermore, we demonstrated that SHP-
1-deﬁcientviablemoth-eatenmiceinfectedwithL.major did
not develop footpad swelling and had signiﬁcantly reduced
parasitic loads [58]. This decreased pathology was associated
withincreaseactivatedneutrophilrecruitmenttothefootpad
a n dm o r ei N O Sm R N Ae x p r e s s i o n[ 58].
As to how Leishmania is able to activate SHP-1, it has
been proposed that Leishmania’s elongation factor-1α (EF-
1α) is responsible for the activation of host SHP-1 seen 16
hours after infection [59]. This report cannot explain, how-
ever, how SHP-1 is activated in earlier infection times nor
does it explain how EF-1α of the parasite can shuttle from
the phagolysosome where the parasite is to the cytosol where
SHP-1 is found. A more plausible mechanism has been re-
cently suggested by our group, where SHP-1 was shown to be
activated via cleavage by the parasite’s protease gp63, which
gains access to the cytosol by going through the lipid raft of
host M∅s[ 47].
Collectively, it appears that the rapid activation of SHP-1
by Leishmania is a key host evasion step whereby the parasite
is able to utilize this phosphatase to negatively regulate
several key M∅ pathways and render them unresponsive
to activating stimuli such as IFN-γ and LPS. By doing so,
the parasite is able to block several M∅ functions such as
NO production and the synthesis of many proinﬂammatory
cytokines that can be deadly to the parasite if allowed to be
produced.
4. Macrophage Functions Altered
by Leishmania
ModulationofsignallingpathwaysbyLeishmaniaisintended
to alter critical M∅ functions to the advantage of the
parasite. Upon the initial contact of Leishmania with the
M∅,certainfunctionssuchastheproductionofchemokines
and chemokine receptors are induced, whereas others are
inhibited. Among the functions inhibited by the parasite are
those related to M∅ activation and to their ability to present
Ag and communicate with cells of the adaptive immune
system. Hereby, we will discuss the main functions that
Leishmania can interfere with initial interaction (0–6h) or
chronic infection (>6h)ofhostM∅s.
One of the important early challenges confronted by
Leishmania is the ability to preferentially recruit cells of the
immune system to the site of inoculation in order to infect
them and establish disease in the host without getting killed.
One key mechanism by which the parasite is able to do so
is the induction of chemokine expression and productionJournal of Tropical Medicine 5
by host immune cells. One study showed that infection
of mice with L. major upregulated the gene expression
of several chemokines (RANTES/CCL5, MIP-1α/CCL3, IP-
10/CXCL10, and MCP-1/CCL2) in cells collected from the
footpad and their draining lymph nodes [60]. Additionally,
we have shown that L. major infection caused an upregula-
tionintheexpressionofseveralchemokines(RANTES,MIP-
1α,M I P - 1 β/CCL4, IP-10, MCP-1, and MIP-2/CXCL1) in
cells being rapidly recruited at the site of inoculation [61]. It
is interesting to see that most of these chemokines are mono-
cyte chemoattractants, recruiting M∅s to infected tissues
and helping the parasite get installed. It is equally interesting
to see that none of these chemokines, with the exception of
MIP-2, attract neutrophils. This is in accordance with our
previous ﬁnding that exacerbated neutrophil recruitment to
infection sites is associated with parasite killing in SHP-1
deﬁcient viable moth-eaten mice [58].
So far, we have considered chemokine upregulation as
beneﬁcial to the parasite, yet it is important to bear in
mind that secreted chemokines during Leishmaniasis can
act as a double-edged sword. Whereas selective activation
of chemotactic factors can help the parasite to recruit M∅s
and neutrophils that they can infect and/or utilize during the
initialstepofinfection,treatmentofsusceptibleBALB/cwith
recombinant IP-10 in the early course of L. major infection
has been shown to increase NK cell cytotoxic activity in the
draininglymphnodesandtodriveahealingIFN-γ-mediated
Th1 response [62]. In chronic infections, chemokine types,
amounts, and duration of chemotactic eﬀect have been
implicated in parasite clearance or persistence. For instance,
in visceral Leishmaniasis, clearance of parasites from the
liver is strongly associated with increased late phase IP-10
production and the Th1 eﬀects associated with its presence
[62].Parasitepersistenceinthespleen,ontheotherhand,has
been correlated with sustained MCP-1, but not IP-10 levels
[63].
Whereas Leishmania can modulate selected chemokines,
importantly the inhibition of key microbicidal functions is
crucial for its initial survival. For instance, one of the dangers
that Leishmania encounters recruiting and entering M∅s
is the ability of these cells to produce deadly free radicals
such as NO [64] and reactive oxygen intermediates (ROIs)
[65]. NO is produced by NOS which converts one of the
terminal nitrogens of the guanidino group of L-arginine to
NO producing L-citrulline [66, 67]. The importance of this
free radical in Leishmaniasis was demonstrated by several
groups. An early study showed the ability of activated M∅s
to kill L. major amastigotes by an L-arginine-dependent
mechanism [68]. Later conﬁrmed by the observation that
L-N-monomethyl arginine (L-NMMA), an L-arginine ana-
logueandinhibitoroftheNOpathwaywasabletoinhibitthe
leishmanicidal eﬀect of M∅sa c t i v a t e din vitro with IFN-γ
or LPS. They also showed the ability of NO in cell-free
suspensions to kill the parasite. Importantly, the same group
demonstrated the importance of NO in vivo by rendering
resistant CBA mice susceptible to L. major infection upon
local administration of L-NMMA [64].
However,parasiteisabletoblockitssynthesisinresponse
to stimuli such as IFN-γ [69], but how can Leishmania
achieve this inhibition? A critical role for host SHP-1 has
been proposed. As previously stated, Leishmania has the
ability to rapidly activate SHP-1 in infected M∅sa n db y
doing so can interfere with several molecules involved in
NO production including JAK2, Erk1/2, and the TFs NF-
κB and AP-1. Indeed, SHP-1 deﬁcient M∅s infected with
L. donovani are still able to produce NO in response to
IFN-γ stimulation, unlike infected WT M∅s which are
refractorytoasimilarstimulation[28].Asexpected,theIFN-
γ-mediatedNOproductionininfectedSHP-1deﬁcientM∅s
correlated with successful JAK2 and Erk1/2 phosphorylation
andtheactivationofNF-κBandAP-1.Theseﬁndingsfurther
elucidate the role of SHP-1 activation in parasite survival
and propagation through its ability to contribute to NO
inhibition [28]. Another mechanism involved in the down-
regulation of NO production is by conversion of arginine to
ornithineandureaviathearginasepathway[70].Supporting
this mechanism, recently, it has been shown that arginase
as well as polyamines gene expression are upregulated by L.
amazonensis amastigote [71]. Whereas those latter mecha-
nisms of evasion are to be of general use by all, Leishmania
parasite will need further investigation.
InadditiontoNO,ROIsrepresentanothersourceofdan-
ger to Leishmania. These intermediates include the superox-
ide radical and hydrogen peroxide produced by cells of the
immune system such as neutrophils and M∅si nr e s p o n s e
to various agonists. Although important in parasite killing,
the activity of the respiratory burst in mice was shown to
have an early and transient eﬀect only. This conclusion is
based on the delayed granuloma formation and resolution
of infection seen in respiratory burst-deﬁcient X-CGD mice
infected with L. donovani compared to WT [72]. Despite the
critical role that NO seems to play in Leishmania killing [72],
ROIs do contribute to parasite clearance and are therefore
a target to be inhibited by the parasite. Indeed, L. donovani
has been shown to inhibit the oxidative burst in infected
M∅s[ 15, 73, 74], and this inhibition was in part mediated
by the parasite surface molecules LPG and gp63 [14, 75]
involving PKC inactivation [15]. Interestingly, it was later
shown that LPG of L. donovani promastigotes is able to block
NADPH oxidase assembly at the phagosome membrane
without interfering with p47(phox) phosphorylation and its
ability to form complexes with p67(phox) [76]. L. donovani
amastigotes, on the other hand, were shown to eﬀectively
block superoxide release through inhibiting the phosphory-
lationoftheNADPHoxidasecomponentp47(phox),leading
to defective recruitment of p47(phox) and p67(phox) to the
phagosome [77]. The inhibition of p47(phox) phosphoryla-
tion could be a result of the previously reported ability of
Leishmania amastigotes to inhibit PKC activity [15], which
is reported to be required for p47(phox) phosphorylation
[78]. Downregulation of ROIs seems also to be modulated
by ERK as inhibitor of ERK decreased ROIs production,
increasing the killing of L. amazonensis amastigote, however
this mechanism is not applied to all species as L. major still
survives [79].
In addition to those nitrous and oxygen derivatives, IL-1
and TNF-α have been correlatedwith antimicrobial activities
against bacteria and parasites in vitro and in vivo [80–83],6 Journal of Tropical Medicine
and IL-12 is well known for its ability to promote Th1
diﬀerentiation and to activate NK cells [84]. In regard to
IL-1 and TNF-α, it has been shown that these molecules
are not produced upon a 12h in vitro infection of human
monocytes with L. donovani amastigotes [85]. Interestingly,
preinfection of those cells diminished LPS-mediated IL-1
production, but not IL-1m-RNA, suggesting inhibition at
the translational level [85]. Another study showed that
preincubation of human monocytes with puriﬁed LPG was
able to cause inhibition of LPS-mediated IL-1β secretion
[86]. The role of LPG in IL-1β inhibition was later shown
to involve LPG ability to inhibit IL-1β gene transcription
in a manner dependent on the nucleotide region −310 to
−57 of the promoter region [87]. This inhibitory eﬀect of
LPG on IL-1β gene transcription was suggested to involve
an inhibition of the binding of an activation factor or
an induction of an unknown transcription repressor [87].
Interestingly, a study by our laboratory revealed that SHP-1
deﬁcient mice infected with L. major produced signiﬁcantly
higher amounts of IL-1 and TNF-α compared to their lit-
termates [61], suggesting that Leishmania-induced SHP-1
activity could play a pivotal role in the attenuation of the
inﬂammatory response repressing the proinﬂammatory cy-
tokines production.
IL-12 is another key cytokine inhibited by Leishmania.
This inhibitory eﬀect is necessary for parasite survival given
the established role of this molecule in driving Th1 differ-
entiation and production of IFN-γ by T cells and NK cells,
w h i c hi nt u r nc a na c t i v a t eM ∅s to kill the parasite. It has
been reported that infection of BMDMs with promastigotes
of L. major or L. donovani fails to induce IL-12 production,
both following infection alone and upon subsequent LPS
or heat-killed bacterial stimulation of M∅s[ 88]. Similar
observations were seen when murine M∅sw e r ei n f e c t e d
with amastigotes of L. major and L. mexicana [89]. Further-
more, incubation of activated murine M∅s with LPG led
to the inhibition of IL-12 production by these cells, with
the inhibition occurring at the transcriptional level [90].
The mechanism by which IL-12 is inhibited by Leishmania
remains not fully understood. Roles for the M∅ CR3 [91]
and Fc-γR[ 92] have been proposed. Recently, we have
reported a very interesting mechanism whereby Leishmania
can inhibit LPS-mediated proinﬂammatory functions such
as IL-12 and TNF-α production. We showed that Leish-
mania-induced SHP-1 is able to bind to an evolutionarily
conserved immunoreceptor tyrosine-based inhibitory motif
(ITIM)-like motif (which we renamed kinase tyrosine-based
inhibitory motif (KTIM)) found in the kinase domain
of IL-1 receptor-associated kinase 1 (IRAK-1), causing its
inactivation. SHP-1-bound IRAK-1 is no longer able to
detach from Myeloid diﬀerentiation factor 88 (MyD88) to
bind TNF receptor-associated factor 6 (TRAF6) and activate
downstreamsignallingpathways,thereforeexplaininginpart
how the parasite is able to block LPS-mediated MyD88-
dependent proinﬂammatory functions in host macrophages
[93].
One remarkable tactic the parasite utilizes to subvert
the immune response is its ability to inhibit IFN-γ-in-
duced MHC class II expression in infected M∅s. Indeed,
L. chagasi and L. donovani were both shown to inhibit MHC
II expression in response to IFN-γ stimulation [94–96].
Surprisingly, M∅s infected with L. major or L. amazonensis
showed normal phagocytosis, Ag processing, and MHC II
production,yetthesecellsfailedtopresentparasiticAgstoT-
cell hybridomas [97, 98]. Authors of both studies concluded
thatthefailuretopresentAgstoTcellsisduetotheparasite’s
ability to interfere with the loading of Ags onto MHC II
molecules. Another interesting mechanism to control Ag
presentationisshownbyamastigotesofL.amazonensisbeing
able to internalize MHC II molecules and to degrade them
using their cysteine proteinases [99].
Activation of CD4+ T cells involves a “two-signal model”
whereby two signals are required to activate the T helper
cell. The ﬁrst signal is triggered by the binding of the T-cell
receptor (TCR) to the MHC II-Ag complex on the APC, and
the second is provided by the binding of CD28 or CD40L on
T cells to costimulatory molecules of APCs such as those of
the B7 family or CD40. Interestingly, apart from interfering
with the ﬁrst signal by inhibiting MHC II presentation,
Leishmania has been demonstrated to interfere with M∅
costimulatory signals. L. donovani infection was reported to
block LPS-mediated B7-1 expression in infected M∅s[ 100],
a mechanism that seems to be mediated by prostaglandins
[101]. Furthermore, L. major was reported to interfere with
CD40 signalling in infected M∅s in a p38-dependent man-
ner [31]. This result is very interesting, especially because
previous studies have established a protective role for CD40
in Leishmania major infections [102, 103], while others have
reported that the disruption of CD40/CD40L ligation results
in increased susceptibility to L. amazonensis infection [104].
The increased susceptibility caused by the disruption of
CD40/CD40L ligation was in part due to the inhibition of
iNOS expression [102, 104] and IL-12 production [105]b y
infected M∅s.
So far, we have discussed several mechanisms by which
Leishmania can interfere with key signalling pathways in-
volved in M∅ activation such as the JAK/STAT pathway. We
also discussed alterations that occur to signalling molecules
involved in TLR signalling such as MAPKs and the TFs NF-
κB and AP-1. However, this does not give justice to TLR
signalling, given its extremely important role in the activa-
tion of APCs to kill invading pathogens and/or activate cells
of the adaptive immune system. Equally important are the
strategies developed by pathogens to block TLR signalling
pathways that can lead to undesirable activation of immune
functions. Therefore, the last portion of this review will dis-
cuss TLR signalling and how Leishmania parasite deals with
this important group of pathogen sensors.
5. Modulation of Toll-Like Receptor
Signalling by Leishmania
TLR family members are known for their critical role in
bridging the innate immune response to the adaptive one
throughrecognizingpathogen-associatedmolecularpatterns
(PAMPs). In the light of the ongoing host-pathogen arms
race, the detection of parasite PAMPs by TLRs has two main
implications: ﬁrst, the ability of cells of the immune systemJournal of Tropical Medicine 7
to detect parasites and eliminate them when favourable
conditions are present. Second, the ability of parasites to
counteract TLR detection by interfering with TLR signalling
keepingimmunecellsinaninactivestateandrenderingthem
refractory to subsequent TLR stimulation.
One of the main parasite-derived molecules involved
in TLR binding and activation is GPI-anchored proteins.
Trypanosoma cruzi-derived GPI-anchors were shown to be
detected by TLR2/TLR6 and CD14 and to activate NF-κB
[106, 107], while GIPLs of T. cruzi activated Chinese hamster
ovary (CHO) cells in a TLR4/CD14-dependent manner
[108]. It has been also shown that GPI-mucin of T. cruzi is
able to activate TLR signalling on ﬁrst exposure and induce
tolerance to secondary TLR stimulation [109]. This was
later shown to be mediated by the ability of GPI-mucin to
induce the expression and activation of the serine/threonine
phosphatase PP2A that acts on cellular IRAK-1, MAPKs,
and IκB causing their inhibition and leading to tolerance
[110]. The induction of PP2A was shown to require p38
and NF-κB, the very same molecules PP2A is induced to
inhibit, therefore giving rise to an autoregulatory loop [110].
LPGofLeishmaniaisanotherGPI-anchoredproteindetected
by TLRs. It has been shown that LPG of L. major directly
binds to TLR2 of M∅sa n dN Kc e l l s[ 111, 112] and that
LPG of L. donovani is also detected by TLR2 of activated
M∅s[ 113]. Interestingly, GPI-anchors derived from Plas-
modium falciparum merozoites can induce TNF production
in human monocytes and mouse M∅s through interacting
with TLR1/TLR2 and to a lesser extent TLR4 [114, 115].
Moreover, GPI- anchors of Toxoplasma gondii are detected
by TLR2 and TLR4, which can thus play an important role in
host defense against T. gondii infections [116].
Although less numerous than GPI-anchored ligands,
non-GPI-related ligands represent an important group of
parasite-related molecules detected by TLRs. An example is
the T. cruzi-derived protein Tc52, which is able to induce
proinﬂammatory cytokine production in DCs in a TLR2-
dependent manner [117]. Other important non-GPI ligands
include the DNA of T. cruzi, T. brucei,a n dBabesia bovis,
which are able to activate M∅sa n dD C s[ 118, 119], possibly
through unmethylated CpG motifs [120] detected by TLR9
[121, 122]. TLR3 was recently shown to be upregulated in
IFN-γ-primedM∅sandtoplayaroleintheirleishmanicidal
activity. The silencing of TLR3 led to impaired NO and
TNF-α production in IFN-γ-primed M∅si nr e s p o n s et o
L. donovani infection and increased parasite survival [113].
Given that the only known ligand of TLR3 is dsRNA, the
parasitecomponentthatactivatesTLR3remainsunclear.The
authors ruled out the presence of dsRNA Leishmania virus
infection in their parasite strain and also failed to detect
naturalLeishmania-deriveddouble-strandedRNAstructures
such as rRNA or tRNA [113]. As far as apicomplexans
are concerned, Plasmodium-derived hemozoin crystals were
shown to induce proinﬂammatory cytokines in M∅s[ 123,
124]. Initially, TLR9 was proposed as the binding receptor
of hemozoin [125], this remains controversial as it has been
latershownthatTLR9activationbyhemozoinismediatedby
malaria DNA attached to the crystal and that the activation
o fT L R 9b yh e m o z o i nw a sa b o l i s h e du p o nt r e a t m e n tw i t h
nucleases [126]. In fact, recent data from our laboratory
show that the proinﬂammatory cytokine IL-1β is induced
by hemozoin through the Nod-like receptor family, pyrin
domain containing 3 protein (NLRP3), and the adaptor pro-
tein Asc, which lead to caspase 1 activation [127]. Concern-
ingToxoplasma, a proﬁlin-like protein from T. gondii (PFTG)
activatesTLR11inmousecells[128],andheatshockproteins
and partially puriﬁed preparations isolated from tachyzoites
activate TLR4 and TLR2, respectively [129, 130].
The many parasite-related molecules that are detected
by TLRs suggest an important role for TLR-related signal-
ling molecules in the resistance to parasitic infections [131].
Given the fact that Th1-driving proinﬂammatory responses
are beneﬁcial to the host in several types of parasitic in-
fections, it is not surprising that the activation of the
MyD88-dependent pathway is crucial in the resistance to
many protozoan diseases. Indeed, MyD88-deﬁcient mice are
highly susceptible to T. cruzi [132], T. brucei [122], L. major
[133], and T. gondii [134] infections due to the decreased
inﬂammatoryresponseandtheimpairedproductionofTh1-
associated cytokines such as IL-12 and IFN-γ in these mice.
ItisimportanttomentionthatMyD88-drivenproinﬂamma-
tory events are not always favourable to the host in the ﬁght
against protozoans. The decreased inﬂammatory and Th1
responses in MyD88-deﬁcient mice were seen to improve
pathology and outcome of P. berghei infection in mice. This
suggests that Plasmodium, in this case, utilizes the MyD88-
dependent pathway to cause tissue injury and worsen disease
symptoms [135].
It is quite remarkable that the amount of susceptibility
to several protozoan infections conferred by the absence of
MyD88 is signiﬁcantly higher than that observed when mice
lacking a single TLR are used. This strongly suggests that
several TLRs are simultaneously involved in the recognition
of parasites, thus explaining why the loss of MyD88 can have
a bigger impact on susceptibility compared to the loss of a
single TLR [131]. Nevertheless, deﬁciency of relevant TLRs
increases susceptibility to certain infections. For example,
TLR9-deﬁcient mice have higher parasitemia and mortality
when infected with T. cruzi [121]o rT. brucei [122]. TLR4-
deﬁcientmicearemoresusceptibletoL.major infectionwith
bigger lesion size and parasite loads compared to WT mice
[136, 137], and TLR11-deﬁcient mice are more susceptible
to T. gondii infection manifesting increased cyst formation in
the central nervous system and decreased IL-12 and IFN-γ
production compared to WT mice [128].
TheabilityofTLRstodetectparasitePAMPsputtogether
with the fact that many successful infections are associated
with silent entry to target cells suggests that parasites must
have evasion tactics to block TLR signalling and functions.
Some of these mechanisms have been already described,
while others are still to be discovered. We will hereby discuss
some evasion strategies employed by Leishmania, Plasmodi-
um,a n dToxoplasma.
The ability of Leishmania to interfere with TLR signalling
components has been already discussed in this chapter under
the “signalling pathways altered by Leishmania”s e c t i o n .
These evasion mechanisms include the previously discussed
ability of the parasite to interfere with the activation of all8 Journal of Tropical Medicine
three MAPKs (Erk1/2, JNK, and p38) (see MAPK section)
and its ability to interfere with IκB, NF-κB, and AP-1 (see
TF section). There is also evidence that signalling through
CR1 and CR3, which Leishmania is known to bind to, can
inhibit LPS- and IFN-γ-induced IL-12 production through
impaired STAT-1 phosphorylation [91]. A similar role for
Fc-γR ligation has been proposed [92, 138]. Nevertheless,
very little is known about how the parasite can interfere
withcriticalupstreamproteinsuniquetoIL-1/TLRsignalling
such as members of the IRAK family. Our laboratory has
been interested for many years in exploring mechanisms
utilized by Leishmania to block TLR signalling in M∅s, and
to evaluate the role of host SHP-1 in this process (Figure 1).
Of utmost interest, we have recently established SHP-1 as
a central regulator of TLR signalling which can be exploited
by Leishmania to inhibit IRAK-1 leading to the inability of
M∅s to respond to a wide range of TLR ligand stimulation
including LPS, favoring parasite survival [93].
Other pathogen evasion tactics include the ability of P.
falciparum to cause infected erythrocytes to express P. fal-
ciparum erythrocyte membrane protein 1 (PfEMP1) which
was shown to interact with the scavenger receptor CD36 on
the surface of DCs [139] making the cells that phagocytose
these infected erythrocytes become unresponsive to LPS
stimulation, ultimately leading to defects in T-cell activation
[140–142].
T. gondii is yet another parasite able to block LPS-
m e d i a t e dI L - 1 2a n dT N F - α production, the upregulation of
costimulatory molecules, and the activation of T cells [143–
146]. One way the parasite is able to do so is by activat-
ing STAT3 in IL-10-dependent and -independent manners
[147, 148]. Although this T. gondii-induced inhibition of
subsequent LPS stimulation might somehow resemble LPS
tolerance in that it inhibits MAPKs like p38 [149], impor-
tant diﬀerences between infection and LPS tolerance exist.
Unlike LPS tolerance, T. gondii infection followed by LPS
stimulation resulted in the activation of MKK3 and MKK6
(upstream activators of p38) and in the degradation of IκB
[149]. This suggests that the inactivation of p38 observed
when LPS stimulation is preceded by Toxoplasma infection is
either due to the inhibition of another p38-activating kinase
such as MKK4 or is mediated by a T. gondii-induced MAPK
phosphatase that prevents the phosphorylation-dependent
activation of p38 [131]. It is interesting to note that although
T. gondii infection followed by LPS stimulation causes IκB
activation, the liberated NF-κB fails to translocate to the
nucleus [150, 151]. Later studies suggested that the lack
of NF-κB translocation might actually be due to increased
nuclear export of this TF rather than inhibition of nuclear
import [152].
Collectively, it is clear that TLRs play a crucial role in
mounting innate and adaptive immunity against invading
pathogens. Alteration of TLR signalling by pathogens or by
clinicaldrugscanplayakeyroleintheoutcomeofinfections.
Wehavediscussedingooddetailstrategiesusedbypathogens
or by the clinic to alter TLR signalling. The activation of
MyD88-dependent signalling and Th1 responses can turn
out very useful in the elimination of many pathogens in-
cluding Leishmania. However, these eﬀorts must always
be perceived with caution as exaggerated activation of in-
ﬂammation can cause edema, pain, and tissue injury and
in severe conditions could be deadly. In addition, certain
infectious models like malaria seem to beneﬁt from MyD88-
dependent signalling and inﬂammation in their pathology,
and thus a completely diﬀerent approach should be used
when trying to ﬁght Plasmodium. As opposed to using TLR
ligands which can worsen the disease, TLR agonists could
proveclinicallyeﬀectiveintreatingmalaria.Nevertheless,the
eﬀects of blocking TLR-TLR-L interactions on the ability of
the immune system to ﬁght oﬀ other pathogens that can
be/become present have to be taken into serious considera-
tion.
6. Concluding Remarks
Over the last 15 years, research stemming from our labora-
tory and others has provided strong evidence that parasites
of the Leishmania genus are able to establish themselves and
to propagate within the mammalian host due to its ability
to alter key signalling pathways, therefore interfering with
the induction of critical M∅ functions that can otherwise
threaten parasite survival. Importantly, we have identiﬁed
one key way Leishmania can do so, and this is by exploiting
hostnegativeregulatorymechanismssuchasthemodulation
of M∅ PTPs.
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